Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data (Q33517195)

27 July 2017

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data (English)

1 reference

enzyme replacement therapy

27 July 2017

0 references

0 references

1 reference

M Ries

9

0 references

Roberto Giugliani

4

object named as

R Giugliani

1 reference

27 July 2017

Gere Sunder-Plassmann

object named as

G Sunder-Plassmann

6

0 references

author name string

A Mehta

1

1 reference

27 July 2017

M Beck

2

1 reference

27 July 2017

P Elliott

3

1 reference

27 July 2017

A Linhart

5

1 reference

27 July 2017

R Schiffmann

7

1 reference

27 July 2017

F Barbey

8

1 reference

27 July 2017

J T R Clarke

10

1 reference

27 July 2017

Fabry Outcome Survey investigators

11

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

27 July 2017

1 reference

27 July 2017

374

1 reference

27 July 2017

1986-1996

1 reference

27 July 2017

9706

1 reference

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Validation of the Brief Pain Inventory for chronic nonmalignant pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Agalsidase alfa and kidney dysfunction in Fabry disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Longitudinal studies on the rate of decline in renal function with age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Clinical practice. Nondiabetic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Fabry nephropathy: 5 years of enzyme replacement therapy-a short review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

Treatment of Anderson-Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

CNS manifestations of Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961493-8

7 January 2021

10.1016/S0140-6736(09)61493-8

Identifiers

DOI

1 reference

27 July 2017

1 reference